
Teleflex (TFX) Stock Forecast & Price Target
Teleflex (TFX) Analyst Ratings
Bulls say
Teleflex is continuing its portfolio restructuring initiatives through acquisition and divestitures which, if successfully executed, could lead to significant value creation and upside potential for the company. The recent spin-off or sale of its Urology, Acute care, and OEM businesses, along with the acquisition of Biotonik vascular business, could lead to an acceleration in revenue growth and a higher margin profile for the company in its remaining business lines. While there are some risks and uncertainties surrounding the execution of these transactions, the current valuation of the stock appears to have already priced in these concerns, leaving limited downside risk for investors. Furthermore, potential interest from private equity and recent takeovers in the MedTech space add a floor to the company's valuation and could provide upside potential in the future. Based on the company's recent performance and these strategic moves, there is potential for a higher upside in Teleflex's stock in the long term.
Bears say
Teleflex is facing challenges in executing its pivot towards becoming a leaner company, which could hinder its ability to achieve meaningful revenue growth and EPS upside. The company's recent divestitures and restructuring efforts may take multiple quarters to show results, and the new CEO's past experience may help improve its interventional position but is not a guarantee. The lack of debt paydown in 2026 and potential refinancing in 2027 may also affect the company's financials. Thus, the current outlook for the stock is negative due to uncertainty around the company's ability to achieve its goals within the expected timeline.
This aggregate rating is based on analysts' research of Teleflex and is not a guaranteed prediction by Public.com or investment advice.
Teleflex (TFX) Analyst Forecast & Price Prediction
Start investing in Teleflex (TFX)
Order type
Buy in
Order amount
Est. shares
0 shares